Clinicopathological Features of Craniopharyngioma: A 15-Year Study From a Tertiary Care Center in Pakistan

Saroona Haroon1,2,3, Anoshia Afzal4, Shamail Zia5

  • 1Pathology, King's Mill Hospital - Sherwood Forest Hospitals, NHS Foundation Trust, Ashfield, GBR.

Cureus
|May 3, 2021
PubMed

Insights

Craniopharyngiomas (CPs) are rare brain tumors with a good overall survival rate of 95.2%. This study found a low recurrence rate of 5.8%, though recurrence significantly impacts patient survival.

Area of Science:

  • Neurology
  • Oncology
  • Pathology

Background:

  • Craniopharyngiomas (CPs) are the most common suprasellar tumors, predominantly affecting children.
  • These benign neoplasms arise from epithelial remnants of the craniopharyngeal duct or adenohypophysis.
  • Two subtypes exist: adamantinomatous craniopharyngioma (ACP) and papillary craniopharyngioma (PCP), with ACP being more common in children and having a more aggressive course.

Purpose of the Study:

  • To evaluate the clinicopathological features of craniopharyngiomas (CPs) in the Pakistani population.
  • To assess survival rates and recurrence patterns of CPs.

Main Methods:

  • A retrospective observational study was conducted over 15 years (2001-2015) at Aga Khan Hospital, Karachi.
  • Histopathological data from 207 diagnosed craniopharyngioma cases were reviewed and confirmed.
  • Clinicopathological features, including age, sex, tumor site, symptoms, survival, and recurrence, were analyzed.

Main Results:

  • The mean age at diagnosis was 25.59 years, with a male predominance (65.7%).
  • The suprasellar region was the most common tumor site (71.5%). Headache and vision loss were the most frequent presenting complaints.
  • An overall survival rate of 95.2% was observed, with a recurrence rate of 5.8%.

Conclusions:

  • Craniopharyngiomas are rare brain tumors with a generally good prognosis and low recurrence rates.
  • Tumor recurrence was identified as a significant factor influencing survival in craniopharyngioma patients.
  • Understanding clinicopathological features is crucial for managing CPs and improving patient outcomes.